Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins

NAActive, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

April 1, 2026

Study Completion Date

May 1, 2026

Conditions
Varicose Veins of Lower LimbVarixVascular DiseasesLeg Edema
Interventions
DRUG

"Venarus® (diosmin and hesperidin)"

"Venarus® (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months"

PROCEDURE

Endovenous laser ablation (EVLA) with miniphlebectomy

Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.

OTHER

Elastic compression

All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment

OTHER

Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores

The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment

Trial Locations (1)

Unknown

RyazanSMU, Ryazan

All Listed Sponsors
lead

Ryazan State Medical University

OTHER